Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.1%

Neg 0% Neu 87.1% Pos 0%

Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $288 price target.

Comments

No comments yet. Be the first!